RapamycinFungusV1, Main, Exploration, bibRecord, 001749

The TOR signalling network from yeast to man.

Identifieur interne : 001749 ( Main/Exploration ); précédent : 001748; suivant : 001750

The TOR signalling network from yeast to man.

Auteurs : Claudio De Virgilio [Suisse] ; Robbie Loewith

Source :

The international journal of biochemistry & cell biology [ 1357-2725 ] ; 2006.

RBID : pubmed:16647875

Descripteurs français

KwdFr :
- Animaux (MeSH), Humains (MeSH), Protein kinases (physiologie), Protein-Serine-Threonine Kinases (physiologie), Protéines de Saccharomyces cerevisiae (physiologie), Sérine-thréonine kinases TOR (MeSH), Transduction du signal (physiologie).
MESH :
- physiologie : Protein kinases, Protein-Serine-Threonine Kinases, Protéines de Saccharomyces cerevisiae, Transduction du signal.
- Animaux, Humains, Sérine-thréonine kinases TOR.

English descriptors

KwdEn :
- Animals (MeSH), Humans (MeSH), Protein Kinases (physiology), Protein-Serine-Threonine Kinases (physiology), Saccharomyces cerevisiae Proteins (physiology), Signal Transduction (physiology), TOR Serine-Threonine Kinases (MeSH).
MESH :
- chemical , physiology : Protein Kinases, Protein-Serine-Threonine Kinases, Saccharomyces cerevisiae Proteins.
- physiology : Signal Transduction.
- Animals, Humans, TOR Serine-Threonine Kinases.

Abstract

The target of rapamycin, TOR, is an essential ser/thr protein kinase that functions in two distinct multiprotein complexes, TOR complex 1 and 2. The structure and functions of these complexes have been conserved from yeast to man. TOR complex 1 is inhibited by rapamycin and is thought to couple growth cues to cellular metabolism; TOR complex 2 is not inhibited by rapamycin and appears to regulate spatial aspects of growth such as cell polarity. Work done in a variety of model systems, continues to contribute to our current understanding of this TOR signalling network. Recent studies in flies and mammalian tissue culture cells have elucidated many signalling components upstream of TOR complex 1. These studies also suggest that aberrant mammalian TOR complex 1 signalling contributes to a number of pathologies ranging from metabolic diseases to hyperproliferative disorders and cancers. Consequently the efficacies of rapamycin and related compounds in treating such diseases are being evaluated in clinical trials.

DOI: 10.1016/j.biocel.2006.02.013
PubMed: 16647875

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 001793
to stream Main, to step Curation: 001793

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The TOR signalling network from yeast to man.</title>
<author><name sortKey="De Virgilio, Claudio" sort="De Virgilio, Claudio" uniqKey="De Virgilio C" first="Claudio" last="De Virgilio">Claudio De Virgilio</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology and Molecular Medicine, University of Geneva, 1211 Geneva 4, Switzerland. Claudio.DeVirgilio@medecine.unige.ch</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Department of Microbiology and Molecular Medicine, University of Geneva, 1211 Geneva 4</wicri:regionArea>
<orgName type="university">Université de Genève</orgName>
<placeName><settlement type="city">Genève</settlement>
<region nuts="3" type="region">Canton de Genève</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Loewith, Robbie" sort="Loewith, Robbie" uniqKey="Loewith R" first="Robbie" last="Loewith">Robbie Loewith</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="RBID">pubmed:16647875</idno>
<idno type="pmid">16647875</idno>
<idno type="doi">10.1016/j.biocel.2006.02.013</idno>
<idno type="wicri:Area/Main/Corpus">001793</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001793</idno>
<idno type="wicri:Area/Main/Curation">001793</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001793</idno>
<idno type="wicri:Area/Main/Exploration">001793</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The TOR signalling network from yeast to man.</title>
<author><name sortKey="De Virgilio, Claudio" sort="De Virgilio, Claudio" uniqKey="De Virgilio C" first="Claudio" last="De Virgilio">Claudio De Virgilio</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology and Molecular Medicine, University of Geneva, 1211 Geneva 4, Switzerland. Claudio.DeVirgilio@medecine.unige.ch</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Department of Microbiology and Molecular Medicine, University of Geneva, 1211 Geneva 4</wicri:regionArea>
<orgName type="university">Université de Genève</orgName>
<placeName><settlement type="city">Genève</settlement>
<region nuts="3" type="region">Canton de Genève</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Loewith, Robbie" sort="Loewith, Robbie" uniqKey="Loewith R" first="Robbie" last="Loewith">Robbie Loewith</name>
</author>
</analytic>
<series><title level="j">The international journal of biochemistry & cell biology</title>
<idno type="ISSN">1357-2725</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Protein Kinases (physiology)</term>
<term>Protein-Serine-Threonine Kinases (physiology)</term>
<term>Saccharomyces cerevisiae Proteins (physiology)</term>
<term>Signal Transduction (physiology)</term>
<term>TOR Serine-Threonine Kinases (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Protein kinases (physiologie)</term>
<term>Protein-Serine-Threonine Kinases (physiologie)</term>
<term>Protéines de Saccharomyces cerevisiae (physiologie)</term>
<term>Sérine-thréonine kinases TOR (MeSH)</term>
<term>Transduction du signal (physiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Protein Kinases</term>
<term>Protein-Serine-Threonine Kinases</term>
<term>Saccharomyces cerevisiae Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Protein kinases</term>
<term>Protein-Serine-Threonine Kinases</term>
<term>Protéines de Saccharomyces cerevisiae</term>
<term>Transduction du signal</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Signal Transduction</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
<term>TOR Serine-Threonine Kinases</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Humains</term>
<term>Sérine-thréonine kinases TOR</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The target of rapamycin, TOR, is an essential ser/thr protein kinase that functions in two distinct multiprotein complexes, TOR complex 1 and 2. The structure and functions of these complexes have been conserved from yeast to man. TOR complex 1 is inhibited by rapamycin and is thought to couple growth cues to cellular metabolism; TOR complex 2 is not inhibited by rapamycin and appears to regulate spatial aspects of growth such as cell polarity. Work done in a variety of model systems, continues to contribute to our current understanding of this TOR signalling network. Recent studies in flies and mammalian tissue culture cells have elucidated many signalling components upstream of TOR complex 1. These studies also suggest that aberrant mammalian TOR complex 1 signalling contributes to a number of pathologies ranging from metabolic diseases to hyperproliferative disorders and cancers. Consequently the efficacies of rapamycin and related compounds in treating such diseases are being evaluated in clinical trials.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16647875</PMID>
<DateCompleted><Year>2006</Year>
<Month>09</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2010</Year>
<Month>11</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1357-2725</ISSN>
<JournalIssue CitedMedium="Print"><Volume>38</Volume>
<Issue>9</Issue>
<PubDate><Year>2006</Year>
</PubDate>
</JournalIssue>
<Title>The international journal of biochemistry & cell biology</Title>
<ISOAbbreviation>Int J Biochem Cell Biol</ISOAbbreviation>
</Journal>
<ArticleTitle>The TOR signalling network from yeast to man.</ArticleTitle>
<Pagination><MedlinePgn>1476-81</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The target of rapamycin, TOR, is an essential ser/thr protein kinase that functions in two distinct multiprotein complexes, TOR complex 1 and 2. The structure and functions of these complexes have been conserved from yeast to man. TOR complex 1 is inhibited by rapamycin and is thought to couple growth cues to cellular metabolism; TOR complex 2 is not inhibited by rapamycin and appears to regulate spatial aspects of growth such as cell polarity. Work done in a variety of model systems, continues to contribute to our current understanding of this TOR signalling network. Recent studies in flies and mammalian tissue culture cells have elucidated many signalling components upstream of TOR complex 1. These studies also suggest that aberrant mammalian TOR complex 1 signalling contributes to a number of pathologies ranging from metabolic diseases to hyperproliferative disorders and cancers. Consequently the efficacies of rapamycin and related compounds in treating such diseases are being evaluated in clinical trials.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Virgilio</LastName>
<ForeName>Claudio</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Molecular Medicine, University of Geneva, 1211 Geneva 4, Switzerland. Claudio.DeVirgilio@medecine.unige.ch</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Loewith</LastName>
<ForeName>Robbie</ForeName>
<Initials>R</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2006</Year>
<Month>03</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Int J Biochem Cell Biol</MedlineTA>
<NlmUniqueID>9508482</NlmUniqueID>
<ISSNLinking>1357-2725</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D029701">Saccharomyces cerevisiae Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.-</RegistryNumber>
<NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D017346">Protein-Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C500749">target of rapamycin protein, S cerevisiae</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein-Serine-Threonine Kinases</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D029701" MajorTopicYN="N">Saccharomyces cerevisiae Proteins</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>22</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year>
<Month>11</Month>
<Day>22</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2006</Year>
<Month>01</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2006</Year>
<Month>02</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2006</Year>
<Month>5</Month>
<Day>2</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2006</Year>
<Month>9</Month>
<Day>15</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2006</Year>
<Month>5</Month>
<Day>2</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">16647875</ArticleId>
<ArticleId IdType="pii">S1357-2725(06)00072-0</ArticleId>
<ArticleId IdType="doi">10.1016/j.biocel.2006.02.013</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Suisse</li>
</country>
<region><li>Canton de Genève</li>
</region>
<settlement><li>Genève</li>
</settlement>
<orgName><li>Université de Genève</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Loewith, Robbie" sort="Loewith, Robbie" uniqKey="Loewith R" first="Robbie" last="Loewith">Robbie Loewith</name>
</noCountry>
<country name="Suisse"><region name="Canton de Genève"><name sortKey="De Virgilio, Claudio" sort="De Virgilio, Claudio" uniqKey="De Virgilio C" first="Claudio" last="De Virgilio">Claudio De Virgilio</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001749 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001749 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:16647875
   |texte=   The TOR signalling network from yeast to man.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:16647875" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020

	Serveur d'exploration sur la rapamycine et les champignons
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la rapamycine et les champignons

The TOR signalling network from yeast to man.

The TOR signalling network from yeast to man.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki